Relapsing Remitting Multiple Sclerosis News and Research

RSS
New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Antidepressant may also alleviate multiple sclerosis symptoms

Antidepressant may also alleviate multiple sclerosis symptoms

Ozanimod effective against multiple sclerosis, enters New Drug Approval process with FDA

Ozanimod effective against multiple sclerosis, enters New Drug Approval process with FDA

Common acne medication can slow progress of relapsing-remitting MS, trial shows

Common acne medication can slow progress of relapsing-remitting MS, trial shows

UBC researchers uncover potential adverse reactions of common multiple sclerosis drug

UBC researchers uncover potential adverse reactions of common multiple sclerosis drug

Merck presents data on investigational cladribine tablets in relapsing multiple sclerosis

Merck presents data on investigational cladribine tablets in relapsing multiple sclerosis

Autologous hematopoietic cell transplant may induce sustained remission of multiple sclerosis

Autologous hematopoietic cell transplant may induce sustained remission of multiple sclerosis

Sheffield Teaching Hospitals NHS Foundation Trust sees huge increase in clinical research

Sheffield Teaching Hospitals NHS Foundation Trust sees huge increase in clinical research

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Promising phase II results for ozanimod in MS

Promising phase II results for ozanimod in MS

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab shows relapse prevention benefits over fingolimod in MS

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

Phase II study hints at oestriol effect in multiple sclerosis

Phase II study hints at oestriol effect in multiple sclerosis

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Taking estriol along with conventional medications helps RRMS patients avoid relapses

GATE opens for generic equivalent to glatiramer acetate in MS

GATE opens for generic equivalent to glatiramer acetate in MS

Daclizumab HYP superior to interferon in relapsing–remitting MS

Daclizumab HYP superior to interferon in relapsing–remitting MS

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Quitting smoking may delay secondary progressive MS onset

Quitting smoking may delay secondary progressive MS onset